Robert Alexander, PhD
Chief Executive Officer
Dr. Alexander has been involved in the formation and leadership of numerous biotechnology companies. Dr. Alexander was CEO of ZS Pharma where he led the initial public offering and sale of ZS Pharma to AstraZeneca. Prior to ZS Pharma, Dr. Alexander was a Director at Alta Partners, a venture capital firm, and was also Executive Chairman and interim CEO of SARcode Bioscience. During his time at Alta Partners, he led investments in SARcode Bioscience (acquired by Shire), Lumena Pharmaceuticals (acquired by Shire), ZS Pharma (acquired by AstraZeneca), and Allakos. Prior to Alta Partners, Dr. Alexander was a Principal in MPM Capital’s BioEquities Fund. Robert joined MPM from Genentech, where he worked in the Business Development group.
Dr. Alexander holds a PhD from the University of North Carolina at Chapel Hill and a Bachelor of Science in Zoology from Miami University of Ohio.
Mary Cromwell, PhD
Chief Technical Officer
Dr. Cromwell has more than 30 years’ experience in the biotechnology industry. Prior to joining Allakos, Dr. Cromwell was Vice President for Quality, Drug Substance at Genentech/Roche. She began her career at Genentech in the Pharmaceutical Development group where she developed formulations for several molecules in various stages of development. She has held leadership positions in Protein Analytical Chemistry, Pharmaceutical Development, and Global Biologics Manufacturing Sciences and Technologies & Global Packaging Development prior to her role in Quality. Dr. Cromwell was directly involved in the licensure of numerous Genentech/Roche products, including Avastin® and Perjeta®. She served as a member of the Genentech Foundation Board, a non-profit organization that provided funding to improve the success of students from underrepresented groups in post-secondary STEM education.
Dr. Cromwell received a BS in Chemistry from West Virginia University, an MS in Biophysical Chemistry from the University of California-Berkeley, and a PhD in Pharmaceutical Sciences from the University of Colorado-Denver.
Craig Paterson, MD
Chief Medical Officer
Dr. Paterson has more than 25 years of pharmaceutical, biotech experience, and clinical practice. Dr. Paterson has led numerous Clinical Development and Medical Affairs teams resulting in multiple NDAs, supplemental new drug applications (sNDAs), and biologic license applications (BLAs) in gastrointestinal diseases and other indications. Prior to joining Allakos, Dr. Paterson was the Lead Physician for Immunodermatology at UCB Pharma. He was also a co-founder and CMO of Vivelix Pharmaceuticals, Senior Vice President of Medical and Clinical Development at Salix Pharmaceuticals, and additionally, has held various positions of increasing responsibility at GlaxoSmithKline, King Pharmaceuticals and Endo International.
Dr. Paterson previously served as Chief, Colon and Rectal Surgery, Associate Professor of Surgery at University of Massachusetts Medical School and Assistant Professor of Surgery at McMaster University Medical Center. Dr. Paterson holds an MD and an MSc (physiology and pharmacology) from McMaster University, Ontario, Canada and an MBA from the University of Tennessee.
CHIEF FINANCIAL OFFICER
Mr. Radford has over 25 years of public company finance and leadership experience at companies in multiple industries and various stages of growth including providing financial operations leadership to commercial-stage companies. Prior to Allakos, as Senior Vice President of Finance at Aimmune Therapeutics, Mr. Radford was responsible for all aspects of strategic and operational finance activities supporting the launch of its first approved product, including financial planning, controllership, tax and treasury functions. Prior to working at Aimmune Therapeutics, he served as the Chief Financial Officer at HeartFlow, a medical technology company with commercial operations in the United States, Canada, Europe and Japan. Prior to joining HeartFlow, Mr. Radford served as Vice President of Finance at Intuitive Surgical, with responsibility for financial planning and analysis, investor relations and enterprise analytics. Prior to Intuitive Surgical, Mr. Radford held various positions at eBay, including Vice President of Finance for Marketplaces Europe, as well as Vice President, Corporate Controller, and Chief Accounting Officer. Mr. Radford began his career in the audit practice of PricewaterhouseCoopers.
Mr. Radford has a BBA from Ohio University.
Adam Tomasi, PhD
Prior to joining Allakos, Dr. Tomasi was Chief Scientific Officer and Head of Corporate Development at ZS Pharma where he led scientific, business development, and investor relation functions through the company’s initial public offering and sale to AstraZeneca. Before joining ZS Pharma, Dr. Tomasi was a Principal at Alta Partners where he contributed to investments in ZS Pharma (acquired by AstraZeneca), Lumena Pharmaceuticals (acquired by Shire), Excaliard (acquired by Pfizer), ChemGenex (acquired by Cephalon), Achaogen, Immune Design and Allakos. Dr. Tomasi served as a drug discovery scientist with Gilead Sciences and Cytokinetics.
Dr. Tomasi holds a Bachelor of Science in Chemistry from the University of California, Berkeley, an MBA from MIT and a PhD in Chemistry from the University of California, Irvine.
Brad Youngblood, PhD
Vice President, Research & Preclinical Development
Dr. Youngblood joined Allakos in 2015 and has held positions of increasing responsibility throughout his tenure. He has over 10 years of experience in pre-clinical and antibody development and is an author and inventor on numerous publications and patents related to inhibitory receptor biology and function. Before joining Allakos, Dr. Youngblood was a scientist in the cancer immunology group at OncoMed Pharmaceuticals.
Dr. Youngblood holds a Bachelor of Science from Baylor University and PhD in Cell Biology and Biochemistry from Texas Tech University Health Sciences Center.